Clinical trial
Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA)
NCT00034853 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00034853 |
|---|---|
| Title | Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) |
| Official title | A 12 Week Double-blind Randomized Trial, With a 12 Week Open-label Extension, to Investigate the Efficacy and Safety of Meloxicam Oral Suspension Administered Once Daily and Naproxen Oral Suspension Administered Twice Daily in Children With Juvenile Rheumatoid Arthritis |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Arthritis, Juvenile Rheumatoid |
| Intervention type | Drug |
| Interventions | meloxicam oral suspension, naproxen oral suspension |
| Enrollment | 180 |
| Start date | Dec 1, 2000 |
| Primary completion | Jun 1, 2003 |
| First posted | May 3, 2002 |
| Last update posted | Nov 1, 2013 |
| Countries | Brazil, Mexico, Ukraine, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: